周一，H.C. Wainwright调整了对Alector Inc. (NASDAQ:ALEC)股票的展望，将目标价从之前的35.00美元大幅下调至7.00美元，但仍维持买入评级。这一决定是在Alector宣布其针对阿尔茨海默病患者的TREM2抗体AL002的Phase 2 INVOKE-2试验未能达到主要终点后作出的。

周二，Morgan Stanley调整了对Alector Inc. (NASDAQ:ALEC)股票的立场，将其评级从持平下调至减持。该公司还大幅下调了目标价格，将其从之前的10.00美元大幅下调至3.00美元。

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Jeffrey Hung has given his Sell rating due to a combination of factors, primarily driven by the unfavorable ...

The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...